science
-
A “muddy intervention”: The complex reality of taVNS therapy for Long COVID
People are experimenting with transauricular vagus nerve stimulation (taVNS), with mixed results, ahead of medical guidelines
-
U.S. scientists sequence 1,000 genomes from measles, a disease long eliminated with vaccines
This week, the Centers for Disease Control and Prevention posted online its first large tranche of advanced genetic data from measles viruses spreading last year. Scientists with knowledge of the operation expect the agency to post heaps more in weeks to come, revealing whether the U.S. has lost its hard-won measles elimination status.
-
“It felt like a life-or-death choice”: Pregnancy with Long COVID has many unknowns
Little is known so far about how people with Long COVID experience pregnancy, but some insights can be gleaned from myalgic encephalomyelitis (ME) as well as several ongoing studies in this area.
-
Despite Long COVID’s ongoing impact, research in Colombia is limited
One of the few Long COVID research studies in Colombia is testing cognitive rehabilitation therapy. This approach recently failed in a U.S. clinical trial.
-
International Long COVID conference spotlights biomarker and mechanism research
The event, now in its third year, also revealed updates about clinical trials and healthcare for the disease.
-
Less than 20% of Long COVID trials involving exercise even mention post-exertional malaise
An analysis by The Sick Times find that less than 15% of Long COVID clinical trials testing the benefits of exercise or cardiopulmonary rehabilitation measured post-exertional malaise, according to their trial registration, while a handful excluded participants who experience it.
-
Live blog: PolyBio’s Fall 2025 Symposium shares Long COVID and related disease research updates
Leading Long COVID and related disease researchers are set to present updates to their work today at the PolyBio Research Foundation’s Fall 2025 Symposium. PolyBio supports some of the most highly-anticipated research projects in infection-associated chronic conditions (IACCs).
-
Metformin has been shown to reduce the risk of Long COVID. Why isn’t it more widely used?
Recent studies add evidence to a prior phase 3 clinical trial, suggesting that taking the diabetes drug during acute COVID-19 reduces the risk of long-term symptoms.
-
Nicotine patches help relieve symptoms in some people with Long COVID. Can the science behind it lead to future therapies?
Some people with Long COVID and the providers who were treating them wondered if nicotine, delivered by a mechanism other than cigarettes, might help with the chronic disease. For the next several years, white papers used anecdotal evidence to expand on that initial hypothesis.
-
Vyvgart brought us back to life, but the Long COVID trial was canceled. We are calling on the NIH and HHS to study the drug.
We are a group of 53 individuals with Long COVID from across the U.S. In 2023, we joined a Long COVID clinical trial for Vyvgart (efgartigimod), a drug approved by the Food and Drug Administration (FDA) for the autoimmune disease myasthenia gravis. Without warning, the trial was canceled in June 2024.
Follow Us
get the latest long covid news
Trending
Recent ARTICLES
Tags
advocacy arts CDC clinical trials commentary COVID-19 precautions disability essay government policy H5N1 healthcare HHS influenza international Long COVID in children masks and respirators ME ME/CFS medical education national COVID-19 trends NIH NIH RECOVER podcast public health research update science Trump administration updates and events vaccines wastewater surveillance